OTC: AAVXF - ABIVAX Société Anonyme

半年間の収益性: -37.47%
配当利回り: 0.00%
セクタ: Healthcare

プロモーションスケジュール ABIVAX Société Anonyme

詳細なスケジュール 簡易グラフ
Financial Markets by TradingView

会社について ABIVAX Société Anonyme

ABIVAX Société Anonyme, a Phase 3 clinical stage biotechnology company, focused on developing therapeutics that modulate the immune system to treat patients with chronic inflammatory diseases. Its lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of ulcerative colitis. The company is also developing obefazimod in Phase IIb/III pivotal planned studies for the treatment of Crohn's Disease; and completed Phase IIa clinical trials for the treatment of rheumatoid arthritis diseases.

さらに詳しく
In addition, the company develops ABX 196, an immune enhancer candidate that is in Phase 1/2 POC clinical trial for the treatment of hepatocellular cancer, as well as a pre-clinical drug for the treatment of respiratory syncytial virus. It has license agreement with the French National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.
比較リストに追加
ウォッチリストに追加
ポートフォリオに追加
価格通知を追加

Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета eur
Сайт https://www.abivax.com
Цена ао 6.91
1日あたりの価格変動: 0% (6.91)
週ごとの価格変動: 0% (6.91)
月ごとの料金変更: +17.32% (5.89)
3ヶ月間の価格変動: -6.24% (7.37)
半年間の価格変動: -37.47% (11.05)
年間の価格変動: -36.89% (10.95)
3年間の価格推移: -73.01% (25.6)
5年間の価格推移: -58.87% (16.8)
年初からの価格変動: -6.24% (7.37)
すべてのパラメータ

過小評価

名前 意味 学年
P/S 86.25 1
P/BV 2.03 7
P/E 0 0
EV/EBITDA -1.54 0
合計: 4

効率

名前 意味 学年
ROA, % -45.17 0
ROE, % -75.37 0
合計: 0

配当金

名前 意味 学年
Div yield, % 0 0
DSI 0 0
合計: 0

義務

名前 意味 学年
Debt/EBITDA -0.4212 10
合計: 9.6

成長の衝動

名前 意味 学年
収益性 Revenue, % 19991.3 10
収益性 Ebitda, % 300.08 10
収益性 EPS, % 15.22 3
合計: 8.6
さらに詳しく

機関 音量 共有, %
iShares MSCI EAFE Small Cap ETF 72366 0.12
abrdn World Healthcare Fund 37000 0.06
College Retirement Equities Fund-Stock Account 26827 0.04
Fidelity SAI International Small Cap Index Fund 9418 0.01
SSgA SPDR ETFS Europe I-SPDR MSCI Europe Small Cap UCITS ETF 7659 0.01
State Street Inst Inv Tr-State St All Cap Glb Equity ex-US Index Port 3874 0.01
iShares MSCI Europe Small Cap ETF 3094 0
SSgA SPDR ETFS Europe I-SPDR MSCI Europe Small Cap Value Weighted 2172 0
SPDR (R) Portfolio Europe ETF 520 0
DBX ETF Trust-X-trackers MSCI Eurozone Hedged Equity 194 0



スーパーバイザー 役職 支払い 生年
Dr. Philippe Pouletty M.D., Ph.D. Founder & Director N/A 1958 (67 年)
Mr. Marc M. P. de Garidel M.B.A. CEO & Director 850.26k 1958 (67 年)
Mr. Didier Blondel EVP, CFO & Board Secretary N/A 1964 (61 年)
Mr. Didier Scherrer Ph.D. Chief Scientific Officer N/A 1970 (55 年)
Mr. Patrick Malloy Senior Vice President of Investor Relations N/A
Ms. Ida Hatoum Chief People & Compliance Officer N/A 1975 (50 年)
Mr. Pierre Courteille M.B.A. Chief Business Officer N/A 1969 (56 年)
Mr. Michael Ferguson B.S., M.B.A. Chief Commercial Officer N/A 1978 (47 年)
Mr. Jerome Denis Ph.D. Executive Vice President of Process Development & Manufacturing N/A
Ms. Ana Sharma M.P.H. VP & Global Head of Quality

住所: France, Paris, 7-11 boulevard Haussmann - Googleマップで開く, Yandexマップを開く
Webサイト: https://www.abivax.com